Common use of JSC Functions and Powers Clause in Contracts

JSC Functions and Powers. The JSC will be responsible generally for facilitating the Parties’ interactions under this Agreement and specifically for overseeing the Development, Manufacture and Commercialization of the COVID Products. The JSC has (i) no jurisdiction to make any amendments to this Agreement, which right is reserved to the Parties; and (ii) no jurisdiction over any dispute relating to the validity, performance, construction or interpretation of this Agreement. The principal functions of the JSC will include: (i) overseeing the Development of Collaboration COVID Vaccine Products in accordance with the COVID R&D Plan(s); (ii) approving Product Adjustments; (iii) approving the development of Pathogen Combination Products; (iv) updating the initial COVID R&D Plan to include the further Development work; (v) discussing and agreeing the Development budgets under the COVID R&D Plan(s); (vi) the resolution and approval of any issue and recommendation from the Parties with respect to the modification of the COVID R&D Plan(s), including but not limited to modifications of the budget and timelines; (vii) receiving written reports or presentations from GSK and CureVac of their respective progress with the further Development of each COVID Product summarizing their Development activities and the results thereof with respect to the applicable COVID Product and discuss at meetings the status, progress, and results of the Development of the respective COVID Product;

JSC Functions and Powers. The JSC will be responsible generally for facilitating the Parties’ ' interactions under this Agreement and specifically for overseeing the Development, Manufacture and Commercialization of the COVID Products. The JSC has (i) no jurisdiction to make any amendments to this Agreement, which right is reserved to the Parties; and (ii) no jurisdiction over any dispute relating to the validity, performance, construction or interpretation of this Agreement. The principal functions of the JSC will include:: ​ ​ (i) overseeing the Development of Collaboration COVID Vaccine Products in accordance with the COVID R&D Plan(s)Plans, including deciding the strategy for the Manufacturing and supply of clinical materials, as referred to in Section 5.3; (ii) reviewing and approving the R&D Plans in relation to a Product AdjustmentsAdjustment, Replacement Product or an Optioned Product; (iii) approving the development of Pathogen Combination Products; (iv) updating the initial COVID R&D Plan Plans to include the further Development work; (v) work and discussing and agreeing approving the annual Development budgets under the COVID R&D Plan(s)Plans; (viiv) the resolution and approval of any issue and recommendation from the Parties with respect to the modification of the COVID R&D Plan(s)Plans, including but not limited to modifications of the budget and timelines; (viiv) receiving written reports or presentations from GSK and CureVac of their respective progress with the further Development of each COVID Product summarizing their Development activities and the results thereof with respect to the applicable COVID Product and discuss at meetings the status, progress, and results of the Development of the respective COVID Product; (vi) exchanging Development Data and other technical information; (vii) upon GSK's request, serving as a forum where CureVac shall inform GSK of new internal development programs covered by GSK's Exclusive Option;

JSC Functions and Powers. The JSC will be responsible generally for facilitating the Parties’ interactions under this Agreement and specifically for overseeing the Development, Manufacture and Commercialization of the COVID Products. The JSC has (i) no jurisdiction to make any amendments to this Agreement, which right is reserved to the Parties; and (ii) no jurisdiction over any dispute relating to the validity, performance, construction or interpretation of this Agreement. The principal functions of the JSC will include: (i) overseeing the Development of Collaboration COVID Vaccine Products in accordance with the COVID R&D Plan(s)Plans; (ii) reviewing and approving the R&D Plans in relation to a Product AdjustmentsAdjustment, Replacement Product or an Optioned Product; (iii) approving the development of Pathogen Combination Products; (iv) updating the initial COVID R&D Plan Plans to include the further Development work; (v) work and discussing and agreeing approving the annual Development budgets under the COVID R&D Plan(s)Plans; (viiv) the resolution and approval of any issue and recommendation from the Parties with respect to the modification of the COVID R&D Plan(s)Plans, including but not limited to modifications of the budget and timelines; (viiv) receiving written reports or presentations from GSK and CureVac of their respective progress with the further Development of each COVID Product summarizing their Development activities and the results thereof with respect to the applicable COVID Product and discuss at meetings the status, progress, and results of the Development of the respective COVID Product; (vi) exchanging Development Data and other technical information; (vii) upon GSK’s request, serving as a forum where CureVac shall inform GSK of new internal development programs covered by GSK’s Exclusive Option;

JSC Functions and Powers. The JSC will be responsible generally for facilitating the Parties’ ' interactions under this Agreement and specifically for overseeing the Development, Manufacture and Commercialization of the COVID Products. The JSC has (i) no jurisdiction to make any amendments to this Agreement, which right is reserved to the Parties; and (ii) no jurisdiction over any dispute relating to the validity, performance, construction or interpretation of this Agreement. The principal functions of the JSC will include: (i) overseeing the Development of Collaboration COVID Vaccine Products in accordance with the COVID R&D Plan(s)Plans; (ii) reviewing and approving the R&D Plans in relation to a Product AdjustmentsAdjustment, Replacement Product or an Optioned Product; (iii) approving the development of Pathogen Combination Products; (iv) updating the initial COVID R&D Plan Plans to include the further Development work; (v) work and discussing and agreeing approving the annual Development budgets under the COVID R&D Plan(s)Plans; (viiv) the resolution and approval of any issue and recommendation from the Parties with respect to the modification of the COVID R&D Plan(s)Plans, including but not limited to modifications of the budget and timelines; (viiv) receiving written reports or presentations from GSK and CureVac of their respective progress with the further Development of each COVID Product summarizing their Development activities and the results thereof with respect to the applicable COVID Product and discuss at meetings the status, progress, and results of the Development of the respective COVID Product; (vi) exchanging Development Data and other technical information; (vii) upon GSK's request, serving as a forum where CureVac shall inform GSK of new internal development programs covered by GSK's Exclusive Option;